www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

   
  home feedback about us  
   
CHINAGATE.OPINION.Population    
Agriculture  
Education&HR  
Energy  
Environment  
Finance  
Legislation  
Macro economy  
Population  
Private economy  
SOEs  
Sci-Tech  
Social security  
Telecom  
Trade  
Transportation  
Rural development  
Urban development  
     
     
 
 
China can lead new fight in war on AIDS


2004-05-18
China Daily

China's leaders have made significant strides in publicizing official HIV/AIDS policy in recent months.

On World AIDS Day, the media was filled with images of Premier Wen Jiabao and Health Minister Wu Yi visiting AIDS patients. A few weeks later Wu Yi visited the so-called "AIDS villages" in Central China's Henan Province, some of which have an infection rates as high as in sub-Saharan Africa.

Last week, we heard about a series of tough new measures being put in place by the new State Council Co-ordinating Committee on HIV/AIDS, measures aimed at preventing the spread of HIV, as well as providing care and treatment for those already infected.

These are powerful statements from the leadership.

As one health official in Beijing put it: "This is what we have all been waiting for."

The government's new attitude is more than just symbolic. Wen and senior health officials announced a "Four Free" policy in poor and rural areas: free testing; free treatment; free school for "AIDS orphans;" and free treatment to prevent mother-to-child transmission of HIV.

If this new policy can be enacted, China will go from having one of the most closed HIV/AIDS policies in Asia to having one of the best such policies in the world.

The big question now is not whether Chinese leaders want to implement these changes - they clearly do - but how to make them a reality.

They face huge problems. China's healthcare system is inadequate, and the marketization of healthcare over the past two decades means doctors and hospitals now largely rely on drug sales for their livelihood. No money, no treatment.

If HIV/AIDS treatment is to be different, doctors will have to be convinced to put the health of AIDS patients before their own profits, and to overcome their fear of treating AIDS patients.

But one of the greatest obstacles China is facing - and one you rarely see mentioned in the headlines - is the stubborn refusal of foreign pharmaceutical companies to make anti-retroviral drugs available at an affordable price in China.

For example, GSK has patented and registered its drug Epivir (r) (also known as Lamivudine or 3TC) in China, but does not actually market it. (3TC is cheap and has far fewer side-effects than other treatments, and for this reason is the backbone of the WHO's "first-line" HIV/AIDS treatment plan worldwide.) GSK doesn't sell Epivir(r), but does sell the same chemical component in a different dosage under the name Heptodin (r) (to treat hepatitis), but at a very high price.

It sells a combination pill, Combivir(r) (3TC plus another drug, AZT), but at almost US$250 per month,so very few Chinese can afford it. Indeed, US$250 would buy more than a year's supply of an equivalent generic in India.

Why is GSK so reluctant? Market surveys show that Heptodin (r) is GSK's best selling drug in China, accounting for somewhere between US$60-80 million in annual sales. But this is business, and it would be unrealistic to expect companies not to make a profit. Still, what multinational pharmaceutical companies are doing in China is anything but healthy competition. Even if the companies lower their prices for anti-AIDS drugs - something they've been talking about for years now - there are likely to be many restrictions on those "discount" prices.

There is a better solution, however. Under the World Trade Organization (WTO) rules, China has the legal right to issue a compulsory licence and produce copies of GSK's patented medicine. They may fear this would be seen as just another case of the Chinese Government failing to respect patents, and that trade officials from Washington and London would protest strongly. On the contrary, in the words of a WHO report on the subject: "If China chooses to proceed with the issuance of compulsory licenses for some essential medicines, it will be showing its commitment to the patent system...rather than ignoring patents or engaging in underground counterfeiting..."

China should now go ahead with such a decision, and set a bold precedent in international trade. China has the technical capacity to supply not only the domestic market but the world's developing countries with cheap, life-saving AIDS drugs.

For years people have spoken of the time when China takes its rightful place in the world of trading nations.

Now it's time for that to become a reality.

 
 
     
  print  
     
  go to forum  
     
     
 
home feedback about us  
  Produced by m.orobotics.cn. All Rights Reserved
E-mail: webmaster@chinagate.com.cn
主站蜘蛛池模板: 亚洲精品手机在线观看 | 亚洲更新 | 日韩国产欧美一区二区三区在线 | 亚洲一级网站 | 日韩一级高清 | 久久成人精品免费播放 | 99精品国产在热久久 | 中文字幕在线精品 | 高清黄色毛片 | 一区二区三区网站在线免费线观看 | 欧美成人猛男性色生活 | 一级黄色录相片 | 一级在线毛片 | 成年人在线观看视频网站 | 免费观看视频成人国产 | 国产精品.com| 亚洲欧洲一级 | 看日本真人一一级特黄毛片 | 在线不卡一区二区 | 自拍偷拍图区 | 精品96在线观看影院 | 国产a一级毛片午夜剧院 | 欧美成人免费观看国产 | 亚洲 欧美 成人日韩 | 91国偷自产一区二区三区 | 日本欧美亚洲 | 久久久久久久性潮 | 久久精品久久精品国产大片 | 大片毛片| 日本久久久久一级毛片 | 亚洲欧美小视频 | 一级一黄在线观看视频免费 | 俄罗斯毛片免费大全 | 日韩专区欧美 | 91热国内精品永久免费观看 | 国产精品免费一区二区三区四区 | 精品欧美日韩一区二区三区 | 美国一级片在线 | 久热国产在线视频 | 国产又色又爽黄的网站免费 | 一级特一级特色生活片 |